

Memorial Sloan Kettering Cancer Center, in collaboration with the National Brain Tumor Society, present

INNOVATIONS IN BRAIN TUMOR MANAGEMENT

APRIL 5-6, 2019

Rockefeller Research Laboratories 430 East 67th Street New York, NY



Memorial Sloan Kettering Cancer Center, in collaboration with the National Brain Tumor Society, present *Innovations in Brain Tumor Management*.

Day 1, Innovations in Brain Tumor Management, will provide an up-to-date review of neuro-oncology, including a review of the most common primary brain tumors, for practitioners. Day 2, Living with a Brain Tumor, will provide attendees education and up-to-date information on medical, behavioral, and social implications of a brain tumor diagnosis, including a multidisciplinary review of care and services available at MSK.

Please note that day 1 is directed towards healthcare providers. We invite patients and caregivers to attend day 2 on a complimentary basis. Please see page 6 for details.

For additional information and registration, visit: mskcc.org/neuro-oncology-course

MSK Program Planning Committee



Thomas J. Kaley, MDDirector, Neuro-Oncology Fellowship Program Department of Neurology



Elena Pentsova, MDAssociate Director, Neuro-Oncology Fellowship Program Department of Neurology



Edward K. Avila, DO

Acting Co-Chair, Department of Neurology
Co-Director, Neuro Advanced Care Unit



Ingo K. Mellinghoff, MDActing Co-Chair, Department of Neurology Chief, Brain Tumor Service

Day 1 Overview

Day 1, Innovations in Brain Tumor Management, will provide an up-to-date review of neuro-oncology including a review of the most common primary brain tumors. An emphasis will be placed on cutting edge innovations in the management of brain tumors essential for practitioners managing neuro-oncology patients. including novel treatment approaches and upcoming biomarker evaluations such as CSF cell free DNA.

Target Audience

The target audience for day 1 includes physicians, trainees, and allied health professionals caring for patients with brain tumors.

Learning Objectives

- Update participants on specific types of brain tumors encountered in clinical practice including low-grade gliomas, glioblastoma, primary CNS lymphoma, and meningioma
- Provide a review of the most cutting edge new and emerging treatment strategies for brain tumors, including targeted therapies, immunotherapies, and CAR T-cell therapies
- Review new and updated strategies for neurosurgical and radiation treatments for gliomas and brain metastases

MSK Course Director (Day 1)



Thomas J. Kaley, MD Director, Neuro-Oncology Fellowship Program Department of Neurology

Join the conversation: #MSKneuro-oncologyCME Be sure to tag **@MSKCME** in your tweets.



Invited Course Faculty



Martin J. van den Bent, MD, PhD Director, Department of Neuro-Oncology The Brain Tumor Center at Erasmus MC Cancer Institute



Christine Brown, PhD

Associate Director, T Cell Therapeutics Research Laboratory; Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology City of Hope



Timothy F. Cloughesy, MD Director, Neuro-Oncology Program; Department of Neurology UCLA Health

MSK Course Faculty



Edward K. Avila, DO

Acting Co-Chair, Department of Neurology Co-Director, Neuro Advanced Care Unit



Kathryn Beal, MD

Associate Attending Department of Radiation Oncology



Cameron W. Brennan, MD

Director, Intraoperative MRI Department of Neurosurgery



Lisa M. DeAngelis, MD

Acting Physician-in-Chief, Memorial Hospital Lillian Rojtman Berkman Chair in Honor of Jerome B. Posner



Eli L. Diamond, MD

Assistant Attending Department of Neurology



Christian Grommes, MD

Assistant Attending Department of Neurology



Ingo K. Mellinghoff, MD

Acting Co-Chair, Department of Neurology Chief. Brain Tumor Service



Gregory J. Riely, MD, PhD

Vice Chair, Clinical Research, Department of Medicine



Robert J. Young, MD

Director, 3T Neuroradiology Imaging Department of Radiology



Jedd D. Wolchok, MD, PhD

Chief, Melanoma & Immunotherapeutics Service Director, Parker Institute for Cancer Immunotherapy at MSK

Day 1 Schedule

FRIDAY, APRIL 5

8:00 ам	Registration & Breakfast
8:30 ам	Welcome & Introduction Thomas J. Kaley, MD
8:40 AM	Advances in Neuroimaging Robert J. Young, MD
9:00 ам	Lower Grade Glioma: at the end of the first stage? Martin J. van den Bent, MD, PhD
9:30 ам	Seizure Management in Glioma Edward K. Avila, DO
9:50 ам	Q&A
10:00 ам	Break
10:10 ам	Innovations in Glioma Surgery Cameron W. Brennan, MD
10:30 ам	Radiation Therapy for Glioma Kathryn Beal, MD
10:50 ам	CAR T cell Therapy for Glioma Christine Brown, PhD
11:20 ам	Evaluation of Novel Agents in Glioblastoma Timothy F. Cloughesy, MD
11:50 ам	Q&A
12:00 рм	Lunch
1:00 рм	Advances in Immune Checkpoint Inhibition Jedd D. Wolchok, MD, PhD
1:30 рм	Evolving Therapies for Brain Metastases Gregory J. Riely, MD, PhD
2:00 рм	Meningioma Thomas J. Kaley, MD
2:20 рм	Q&A
2:30 рм	Break
2:40 рм	Precision Medicine Approaches in Neuro-Oncology Ingo K. Mellinghoff, MD
3:00 рм	CNS Lymphoma Christian Grommes, MD
3:20 рм	Histiocytosis and Erdheim-Chester Disease Eli L. Diamond, MD
3:40 рм	Q&A
3:50 рм	Closing Remarks and Perspectives Lisa M. DeAngelis, MD
4:10 рм	Adjourn
4:10 рм	Networking Reception Attendees are invited to join the course faculty for a networking reception from 4:10-5:30 PM in Rockefeller Research

Day 2 Overview

Day 2, Living with a Brain Tumor, will provide attendees education and up-to-date information on medical, behavioral, and social implications of a brain tumor diagnosis. It will introduce the multidisciplinary care clinic (MDCC) and services available at MSK for patients and caregivers to address coping skills and improve quality of life after brain tumor diagnosis. In addition to lectures, the conference will include opportunities for interactive conversation between participants and faculty.

Target Audience

The **target audience for day 2** includes patients with primary brain tumors, caregivers of patients with brain tumors, nurses, residents, fellows, neurologists, neuro-oncologists, social workers, rehabilitation medicine physicians, case managers, physical therapists and occupational therapists.

Learning Objectives

- Update participants on principle and rationale of clinical trials
- Learn about patient and caregiver services offered at MSK
- Introduce the multidisciplinary care clinic model-consisting of nurses, physical therapist, rehabilitation medicine doctor, nutritionist, case manager, social worker, and spiritual adviser.

MSK Course Director (Day 2)



Elena Pentsova, MDAssociate Director, Neuro-Oncology Fellowship Program Department of Neurology

MSK is pleased to invite patients and caregivers to attend day 2 on a complimentary basis. Attendees are welcome to join in person or view a live simulcast of the event.

Please email **cme@mskcc.org** to register.

(Include your name, email address, phone number and whether you will be attending in person or prefer to view the live simulcast)

MSK Course Faculty



Yesne Alici, MD, FACLP, FAPM Clinical Director, Psychiatry Service Department of Psychiatry



Allison J. Applebaum, PhDPsychologist
MSK Counseling Center



Dana Bossert, RN, BSN, OCN Nursing Coordinator, ECD Registry



Alan Carver, MDAttending Neurologist
Department of Neurology



Dominique Jean-Charles, MSN, MPH, RN, CCM Nurse Case Manager - Case Management Department



Thomas J. Kaley, MDDirector, Neuro-Oncology Fellowship Program
Department of Neurology



Brian C. Kelly Chaplain



Ingo K. Mellinghoff, MD
Acting Co-Chair, Department of Neurology
Chief, Brain Tumor Service



Lisa Ruppert, MDAssistant Physiatrist,
Department of Neurology
Assistant Director, Cancer Rehabilitation Medicine Fellowship



Maryann Sibilla, BSN, RN Registered Nurse Outpatient Services



Anastasia Zankowsky, LMSW Clinical Social Worker

Invited Patient/Caregiver Speakers

Ruth Kavanagh Catherine Cronin David C. Cronin, MD, PhD, MHCM, FACS, FACHE Sabine Schwab, PhD

Day 2 Schedule

SATURDAY, APRIL 6

8:30 AM	Breakfast
9:00 AM	Welcome & Introduction Elena Pentsova, MD
9:05 ам	General Overview of Brain Tumor Therapies Ingo K. Mellinghoff, MD
9:25 ам	Patient and Practictioners' Views on Clinical Trials Thomas Kaley, MD Dana Bossert, RN, BSN, OCN
9:45 ам	Q&A
9:50 AM	Break
9:55 ам	Patient Stories Ruth Kavanagh
	Catherine Cronin and caregiver, David C. Cronin, MD, PhD, MHCM, FACS, FACHE
10:10 ам	Maintaining and Improving Mobility Lisa Ruppert, MD
10:30 ам	Coping with Brain Tumor Diagnosis Yesne Alici, MD, FACLP, FAPM
10:50 ам	Caregiver Burden: What To Do About It and How to Prevent It! Allison J. Applebaum, PhD
11:10 ам	Q&A
11:20 ам	Patient Story Sabine Schwab, PhD
11:30 ам	Treating the Whole Patient from a Nursing Perspective Maryann Sibilla, BSN, RN
11:40 ам	Multidisciplinary Care Clinic Elena Pentsova, MD Lisa Ruppert, MD Anastasia Zankowsky, LMSW Dominique Jean-Charles, MSN, MPH, RN, CCM Maryann Sibilla, BSN, RN Brian C. Kelly
12:00 рм	Closing Remarks Alan Carver, MD
12:15 рм	Lunch and Networking with Faculty/Patients/Caregivers

Live Simulcast Available for Patients and Caregivers

Patients and caregivers are welcome to attend this course on a complimentary basis either in person or via a live simulcast. Please note that registration is required for either option.

Early	General
\$300	\$350
\$100	\$150
\$575	\$625
	\$75
	\$300 \$100

^{*}Early registration expires March 1, 2019

Register Online:

mskcc.org/neuro-oncology-course

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

- MSK is pleased to invite patients and caregivers to attend day 2 on a complimentary basis. Please email cme@mskcc.org to register (include your name, email address, phone number and whether you will be attending in person or prefer to view the live simulcast)
- MSK CME offers a 30% discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
- MSK employee registration is complimentary. However, you must complete course registration in order to attend this course.

Symposium Location

Memorial Sloan Kettering Cancer Center Rockefeller Research Laboratories 430 East 67th Street New York, NY

Accommodations

For information on hotels in the vicinity of MSK with discounted rates, please visit: mskcc.org/cme.

Contact

Memorial Sloan Kettering Cancer Center Office of Continuing Medical Education mskcc.org/cme cme@mskcc.org



Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.



AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **9.50** *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC CNE Statement*

Memorial Sloan Kettering Cancer Center – Nursing Professional Development/Continuing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.



3.10 CNE contact hours will be awarded to participants who attend a live program, in its entirety, and complete a program evaluation. Partial credit not awarded.

*Please note that ANCC CNE contact hours are only available for day 2.

Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

^{**}Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.